GSK's down as ovarian cancer drug suffers setback on safety issue

Clovis Oncology

11/11/2022 15:06

** U.S. shares of drugmaker GSK  GSK.N  fall 5.6% to $31.58 
    ** Co said it will limit the use of its ovarian cancer drug,
Zejula, in the United States as a second treatment option 
    ** The drug, Zejula, belongs to family of drugs called PARP
inhibitors which have recently suffered safety setback
    ** Others similar drugs from AstraZeneca  AZN.L  and Merck's
 MRK.N  Lynparza and Clovis Oncology's  CLVS.O  Rubraca have
suffered similar issues
    ** Including session losses, shares have fallen ~18% YTD
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))